Treatment with mesalamine significantly reduced mTOR levels by 49.75% (F = 528.4, p = 0.004) and downregulated NLRP3 expression by 40.32% (F = 66.14, p = 0.008) compared to the colitis group. This evidence concerns the gene NLRP3 and colitis.